Skip to main content
. 2021 Jul 29:1–11. doi: 10.1080/14728222.2021.1952985

Table 2.

Examples of efficacies of drugs against the enterovirus 3 C protease (3 Cpro) and coronavirus main protease (Mpro)

Drug 3 Cpro Mpro
alpha-ketoamide (11a) [50] 6.56 ± 3.10 (CVB3) 1.95 ± 0.24
alpha-ketoamide (11 r) [50] 0.95 ± 0.15 (CVB3) 0.71 ± 0.36
alpha-ketoamide (11 u) [50] 1.93 ± 0.43 (CVB3) 1.27 ± 0.34
PF-00835231 [51] 1.70 ± 1.00 (HRV) 0.004 ± 0.0003
43,146 [52] 5.40 ±- 0.20 (CVB3) 8.10 ± 0.90
PSI [54] 13.74 ± 3.86 (EV-A71) 10.38 ± 2.90*
GC-376 [54] 0.14 ± 0.03 (EV-A71) 0.03 ± 0.01*
Calpain inhibitor II [54] >20 (EV-A71) 0.97 ± 0.27*
Calpain inhibitor XII [54] >20 (EV-A71) 0.45 ± 0.06*
MAC-5576 [53] 0.54 ± 0.09 (HAV) 0.50 ± 0,.0
MAC-22,272 [53] 0.90 ± 0.10 (HAV) 2.60 ± 0,.0

IC50 valuesIC50 values

IC50 values (µM) of drugs tested against marked enterovirus 3 Cpro and SARS-CoV-1 Mpro. *Tested against SARS-CoV-2